The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)
evaluation of the efficacy of transarterial chemoinfusion (TAI) combine lenvatinib in advanced hepatocelllar carcinoma
Hepatocellular Carcinoma
COMBINATION_PRODUCT: TAI combine lenvatinib|DRUG: Lenvatinib
OS, overall survival, From date of randomization until the date of death from any cause, assessed up to 60 months|PFS, progression-free survival, From date of randomization until the date of progress from any cause, assessed up to 60 months
ORR, object response rate, From date of randomization until the date of death from any cause, assessed up to 60 months|DCR, disease control rate, From date of randomization until the date of death from any cause, assessed up to 60 months
evaluation of the efficacy of transarterial chemoinfusion (TAI) combine lenvatinib in advanced hepatocelllar carcinoma